GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Forward PE Ratio

Sigyn Therapeutics (Sigyn Therapeutics) Forward PE Ratio : 0.00 (As of Jun. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Forward PE Ratio?

Sigyn Therapeutics's Forward PE Ratio for today is 0.00.

Sigyn Therapeutics's PE Ratio without NRI for today is 0.00.

Sigyn Therapeutics's PE Ratio for today is 0.00.


Sigyn Therapeutics Forward PE Ratio Historical Data

The historical data trend for Sigyn Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Forward PE Ratio Chart

Sigyn Therapeutics Annual Data
Trend
Forward PE Ratio

Sigyn Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Sigyn Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Sigyn Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sigyn Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Forward PE Ratio falls into.



Sigyn Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sigyn Therapeutics  (OTCPK:SIGY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sigyn Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sigyn Therapeutics (Sigyn Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Executives
Joseph Segelman director, 10 percent owner, officer: President & CEO 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp 10 percent owner 9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman director, officer: Secretary 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212